Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brigham & Women's Hospital, Boston
Inhibition of histone deacetylation may provide valuable approach for lung cancer therapy
May 8th, 2006
Inhibition of histone deacetylation may provide a valuable approach for lung cancer treatment. According to recent research from the United States, "A well-known histone deacetylase inhibitor, trichostatin A, was applied to non-small cell lung cancer cells to determine whether inhibition of histone deacetylase leads to the production of proteins that either arrest tumor cell growth or lead to tumor cell death. Trichostatin A (0.01-1.0 mc mol/L) was applied to 1 normal lung fibroblast and 4 non-small cell lung cancer lines, and its effect was determined by flow cytometry, annexin-V staining, immunoprecipitation, and Western blot analysis. Trichostatin A demonstrated...
Source: Biotech Week (2006-05-08)
|
